Myelodysplastic Syndrome (MDS) Bone Marrow Mononuclear Cells

Myelodysplastic Syndrome (MDS) Bone Marrow Mononuclear Cells for Hematology Research

Our Myelodysplastic Syndrome (MDS) Bone Marrow Mononuclear Cells is a hematopoietic tissue sample isolated by density-gradient separation from bone marrow aspirate, capturing the full spectrum of marrow-resident hematopoietic stem, progenitor, and precursor cells that peripheral blood samples do not contain. Samples are sourced from IRB-consented donors clinically diagnosed with MDS, a clonal hematopoietic stem cell disorder characterized by ineffective hematopoiesis.

MDS Biology and Why Bone Marrow

• MDS is defined by dysplastic changes across one or more hematopoietic lineages and by marrow blast percentage, both of which require direct marrow evaluation and cannot be assessed from peripheral blood alone.
• Cytogenetic abnormalities, assessed on marrow aspirate, are incorporated into the Revised International Prognostic Scoring System (IPSS-R), the standard tool for risk stratification and treatment planning.
• Marrow blast percentage determines classification and monitors progression risk toward acute myeloid leukemia, a transformation that occurs in a meaningful subset of MDS cases.
• Hypomethylating agents and, in eligible patients, stem cell transplantation are guided by marrow-based risk assessment, making marrow material central to treatment-response research.
• Clonal hematopoiesis and somatic mutation studies (including SF3B1, TET2, and ASXL1) rely on marrow-derived material to characterize disease biology and clonal evolution.

Donor Stratification Available

• IPSS-R risk category where documented
• Marrow blast percentage at collection
• Cytogenetic abnormalities and somatic mutation status where documented
• Treatment history, including hypomethylating agents or transplant
• Age band and sex assigned at birth
• Matched healthy bone marrow controls available

Product Features

• Isolated from clinically confirmed MDS donor bone marrow aspirate
• Density-gradient purified and cryopreserved
• Research Use Only (RUO)
• IRB-approved protocols with documented consent
• Standard and custom cell quantities available

De-identified Donor Data

• MDS diagnosis confirmation and IPSS-R risk category where documented
• Age, sex assigned at birth, and ethnicity
• Donor-reported allergy and infectious disease history
• Treatment history where documented
• Additional MDS-specific metadata available on request

Applications

• Cytogenetic and IPSS-R risk stratification studies
• Somatic mutation and clonal hematopoiesis research (SF3B1, TET2, ASXL1)
• Progression-to-AML biomarker studies
• Hypomethylating agent pharmacodynamic research
• Dysplasia and ineffective hematopoiesis mechanism studies

Other Specimen Types

For matched marrow-derived material across conditions, see our human bone marrow mononuclear cells collection.

Compliance and Quality Assurance

• IRB-approved and HIPAA-compliant protocols
• Electronic informed consent with 21 CFR Part 11-compliant e-signatures
• Documentation support available for regulatory review

Ordering & Customization

MDS bone marrow mononuclear cells are available in standard and custom cell quantities. For pricing, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations.